26th Jul 2021 14:19
Beximco Pharmaceuticals Ltd - Bangladesh-based pharmaceutical company - Receives approval from US Food & Drug Administration for Baclofen, a muscle relaxant drug indicated for the treatment of muscle pain, spasms, and stiffness in people with multiple sclerosis or spinal cord injury or disease.
The company expects to launch the product through its US distribution partner in due course.
According to IQVIA audited market data, there are currently nine active players for Baclofen in the US market, which generated sales of more than USD110 million in 2020.
Current stock price: 81.80 pence, up 6.9% on Monday
Year-to-date change: down 18%
By Amrit Sahota; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Beximco Pharma